Trailing-twelve-month (TTM) revenue is $858.61 Million with a year-over-year growth of +11.68%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $211,872,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $211,639,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-19 |
| Q1 FY2026Period ended 2026-03-31 | $221,743,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $213,355,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $858,609,000 |
Current P/S: $1,995,162,480 market capitalization ÷ $858,609,000 TTM revenue = 2.32x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T18:50:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $213.35M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T18:52:47.616Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| A I U S | N/A | N/A | N/A | N/A | N/A | $226M |
| C T U | N/A | N/A |
$858.61M
$858.61 Million
+11.68%
vs. $768.81M a year ago (TTM)
+4.19%
5 Year compound annual growth rate
1 Year
+11.68%
3 Year
+5.71%
5 Year
+4.19%
10 Year
+1.45%
15 Year
(5.81%)
20 Year
(4.24%)
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $846.10M | +$164.83M | +24.20% |
| 2024 | $681.26M | ($28.74M) | (4.05%) |
| 2023 | $710.00M | +$14.80M | +2.13% |
| 2022 | $695.21M | +$2.17M | +0.31% |
| 2021 | $693.03M | +$5.72M | +0.83% |
| 2020 |
TTM Growth
+11.68%
3-Year CAGR
+5.71%
5-Year CAGR
+4.19%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T18:52:47.616Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| N/A |
| N/A |
| $462M |
| Corporate and Other | N/A | N/A | $1M | N/A | N/A | N/A |
|---|
| Corporate And Other | $446,000 | $1M | N/A | N/A | N/A | N/A |
|---|
| Product and Service, Other | N/A | N/A | N/A | $7M | $5M | N/A |
|---|
| Tuition And Fees Net | N/A | N/A | N/A | $703M | $676M | N/A |
|---|
| University of St. Augustine for Health Sciences, LLC | N/A | N/A | N/A | N/A | N/A | $158M |
|---|
| $687.31M |
| +$59.61M |
| +9.50% |
| 2019 | $627.70M | +$46.41M | +7.98% |
| 2018 | $581.30M | ($15.14M) | (2.54%) |
| 2017 | $596.43M | ($107.96M) | (15.33%) |
| 2016 | $704.39M | ($142.88M) | (16.86%) |
